BETA-3 agonists

1 paper2 findings

In silico1

Outcomes

2

Quality-adjusted life-years

upin silico1

1 study

BETA-3 agonists improve quality-adjusted life-years in silico (8.79 vs 8.65 QALYs).
In silico15 years
Cost Effectiveness Analysis Of Using Beta-3 Agonists Over Anticholinergics For Treatment Of Overactive Bladder In Reducing Risk And Cost Of Anticholinergic-Associated Cognitive Decline
Urology practice28 Aug 2026

Health care costs

downin silico1

1 study

BETA-3 agonists decrease health care costs in silico ($90,961 vs $97,000).
In silico15 years
Cost Effectiveness Analysis Of Using Beta-3 Agonists Over Anticholinergics For Treatment Of Overactive Bladder In Reducing Risk And Cost Of Anticholinergic-Associated Cognitive Decline
Urology practice28 Aug 2026

Latest

1 in 12 months

Urology Practice28 Aug

Cost Effectiveness Analysis Of Using Beta-3 Agonists Over Anticholinergics For Treatment Of Overactive Bladder In Reducing Risk And Cost Of Anticholinergic-Associated Cognitive Decline

Computational studyInterventions